Speciality Medicines Limited IPO Review
Neutral117-124 · SME
✦
Analyst Verdict
Speciality Medicines Limited IPO
Neutral
IPO at a Glance
Price Band
117-124
Issue Size
29cr
Min. Investment
₹1,24,000
Opens
2026-03-18
Closes
2026-03-22
Listing
2026-03-28
Category
SME
Key Strengths
✓Focuses on speciality medicines for complex and chronic diseases.
✓Diverse product portfolio across multiple therapeutic areas.
✓A wide range of dosage forms enhances product reach.
✓Dual business model of manufacturing and distribution.
✓Presence in international markets through a distribution network.
Key Risks
⚠Dependence on third-party manufacturers for product supply.
⚠High reliance on a few key customers for revenue.
⚠Strict quality requirements may lead to order cancellations.
⚠Ongoing legal proceedings involving a promoter.
⚠Exposure to supply disruptions and price volatility.
Frequently Asked Questions
Should I apply for Speciality Medicines Limited IPO?
Based on our analysis, our rating for Speciality Medicines Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Speciality Medicines Limited IPO?
Dependence on third-party manufacturers for product supply. High reliance on a few key customers for revenue. Strict quality requirements may lead to order cancellations.
What are the strengths of Speciality Medicines Limited IPO?
Focuses on speciality medicines for complex and chronic diseases. Diverse product portfolio across multiple therapeutic areas. A wide range of dosage forms enhances product reach.
What is the price band of Speciality Medicines Limited IPO?
The price band for Speciality Medicines Limited IPO is 117-124. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more